Skip to content

Clinical trials

Observational Anemia, Hemolytic, Autoimmune trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Anemia, Hemolytic, Autoimmune Phase: Observational Clear all

20 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20071
20091
20101
20132
20162
20171
20181
20194
20201
20221
20231
20253

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting8
Completed7
Not yet recruiting2
Unknown status2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Institute of Hematology & Blood Diseases Hospital, China4
University Hospital, Bordeaux4
Assiut University3
Centre Hospitalier Universitaire Dijon2
University Hospital, Toulouse2
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico1
Medical University of Graz1
Peking Union Medical College Hospital1
RECORDATI GROUP1
Sanquin Research & Blood Bank Divisions1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Anemia, Hemolytic, Autoimmune20
Purpura, Thrombocytopenic, Idiopathic7
Myelodysplastic Syndromes4
Anemia, Aplastic3
Cytopenia2
Cryoglobulinemia1
Hemoglobinuria, Paroxysmal1
Hemophilia A1
Hemophilia B1
Hemostatic Disorders1

Trials

Showing 51 to 20 of 20. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.